Effective nebuliser therapy requires a device distinguished from a simple atomiser by the incorporation of baffles which selectively rethat repeatedly and quickly delivers sufficient drug to the site of action, with minimal wastage, move large droplets from the outgoing spray. 
Early models were essentially atomisers conat a low cost. Clinicians are bombarded with competing claims about different nebuliser sys-structed of glass and operated manually by compressing a hand bulb attached to the air tems. In many cases, however, insufficient details are available to make the most appropriate inlet tube. 10 In 1946 pumps providing a continuous flow of air were advocated and the choice. The rapid increase in the number of nebulisers marketed and significant differences Collinson nebuliser, 11 constructed of ebonite with a plate baffle to filter out particles larger in design may result in drug delivery to patients varying by a factor of two or more. 1 than 5 m, became the most popular nebuliser in this country. In 1958 Wright 12 described a new nebuliser, considerably more compact than the Collinson, with a moulded perspex top.
Drug delivery from nebulisers
Most of the prescribed medication for nebu-Now discontinued, it found widespread use in bronchial challenge testing. 13 14 lisers never reaches the lungs. 2 Of the dose placed in the nebuliser chamber, perhaps two
With the advent of portable, oil free compressors and injection moulding of plastics, a thirds remains there at the end of nebulisation. Two thirds of the dose released from the nebu-wide variety of disposable nebulisers has become available. Recent advances in their liser may be released during expiration and passes into the surrounding air.
3 Some of the design have considerably altered the amount of drug patients receive. inhaled drug will be in particles too large to reach the lung, and some in particles so small that they do not deposit but are simply exhaled again. With many nebulisers only 10% of the    In a jet nebuliser the driving gas passes through prescribed dose may reach the lung. 4 For bronchodilators, where a small dose may a very narrow hole, known as a Venturi, from a high pressure system (fig 1) . At the Venturi achieve an adequate result, this may not matter. It is more important for drugs with dose related the pressure falls and the gas velocity increases greatly producing a cone shaped front. This effects (and side effects) such as steroids, and for expensive medications such as rhDNase. 5 passes at high velocity over the end of a narrow liquid feed tube or concentric feeding system creating a negative pressure at this point. As a result of this fall in pressure, liquid is sucked Nebuliser types: how they work [6] [7] [8] Nebulisers used in aerosol drug delivery pro-up by the Bernoulli effect (see Appendix 1) and is drawn out into fine ligaments. The duce a polydisperse aerosol where most of the drug released is contained in particles 1-5 m ligaments then collapse into droplets under the influence of surface tension. This primary in diameter. Most nebulisers use compressed air for atomisation (fig 1) , but some use ultra-generation (atomisation) typically produces droplets 15-500 m in diameter. 15 
characteristics determined by the design of the
More aerosol is being pushed out in a given time.
air jet and capillary tube orifices, their geometric relationship with each other and the internal baffles. For a given design the major determinant of output is the driving gas flow. output, cheaper lower specification compressors can be used. If the extra inlet channel (the vent) is blocked, preventing additional flow of air through the chamber, a similar       Conventional jet nebulisers are highly in-amount of drug exits the nebuliser, but over a much longer time. Because of the high flow of efficient as much of the aerosol is wasted during exhalation. Between 93% and 99% of the prim-aerosol from this device, young children with low inspiratory flow may receive less drug than ary droplets are caught on the internal baffles and structures, resulting in a low output. 15 anticipated.
With continuously operated nebulisers at Recent designs have attempted to reduce these inefficiencies.
least 50% of the aerosol is wasted during exhalation. Intermittent nebulisation, during inspiration alone, reduces aerosol waste and contamination of the environment (fig 4) . Man-
Continuous entrainment of gas through the nebuliser (open vent nebulisers)
ual interrupters, however, require coordination by the patient, but the increased efficiency Conventional jet nebulisers produce a fixed flow of gas containing aerosol. Some recent results in longer treatment times. In order to combine the convenience of continuous operdesigns (for example, Sidestream; Medic-Aid, Pagham, UK) incorporate an extra open vent ation and the efficiency of intermittent nebulisation, the Pari LC Plus (Pari, Germany) (fig into the nebuliser in such a way that negative pressure generated by the expansion of com-5) and the Ventstream (Medic-Aid, UK) have been developed. pressed air at the Venturi sucks air into the chamber via the vent as well as fluid from the feeding tubes for atomisation (fig 3) . This results in a continuously greater air flow Entrainment of gas through the nebuliser on inspiration only (breath assisted, open vent through the chamber which pushes more small particles out to be inspired, in a given time, nebulisers)
The Pari LC Plus nebulises continuously, but leading to shorter nebulisation times. The contribution of enhanced air flow through the during inspiration a valve situated on top of the device opens, allowing extra air to be drawn nebuliser in reducing particle size, due to greater solvent evaporation, remains to be de-through the nebuliser. As with the open vent nebulisers, it is claimed that this air will draw termined. Because lower compressed air flows are needed to generate the same respirable a much greater number of particles into the inspired air stream. During exhalation the in-this valve closes and exhaled air passes out of the device through a separate expiratory spiratory valve closes, decreasing the flow of air through the chamber to that from the com-pathway. These "breath assisted, open vent" nebulisers increase the amount of inspired pressor only. The result is that loss of aerosol during expiration is similar to that from a con-drug. Nebulisation time is shorter than conventional jet nebulisers but not as fast as the ventional jet nebuliser.
The Ventstream nebuliser is similar in design open vent design. The advantages of the "breath assisted, open to the Sidestream, but a valve on the side of the device opens only during inspiration, vent devices" are (1) that the additional airflow through the nebuliser draws more of the small allowing air to be drawn through the nebuliser which increases drug output. On exhalation particles generated out to be inspired (increased Smaller, less powerful compressors may not be suitable for all drugs, but there are distinct advantages in having a nebuliser that is small, lightweight and that can run on batteries.
It is important to choose a nebuliser and compressor that work well together. For example, if a "breath assisted, open vent" type of nebuliser is run by a very high flow compressor this may defeat the object of minimising drug wastage on expiration.
 
The ultrasonic nebuliser uses a rapidly vibrating lets break free from the crests of these waves and are released as aerosol. The size of droplets produced is inversely proportional to two thirds of the power of the acoustic frequency (see Appendix 1 on page S42 for mathematical evaporation from droplets may occur so that smaller particles are produced); (2) there is an relationships). Like jet nebulisers, baffles within the nebuliser remove large droplets and much increase in the amount of aerosol delivered to the patient and less wastage of aerosol during of the aerosol produced impacts on these, falling back into the drug reservoir. exhalation (fig 6) so that the dose of drug inspired may be doubled; 1 and (3) lower com-A more recent design of ultrasonic nebuliser (Omron U1, Omron Healthcare) uses the vipressed air flows are needed to generate the same respirable output, allowing cheaper com-bration of the piezoelectric crystal to generate pressors of lower specification to be used.
These systems do have some disadvantages, however. Firstly, they are dependent upon the patient's inspiratory flow for optimum function and more information is needed before they can be recommended for young children. Viscous solutions (such as ceftazidime) may be nebulised slowly if a less powerful compressor is used.
 
Another way of reducing wastage of drug produced during exhalation is to use a holding chamber such as the Mizer aerosol conservation device (Medic-Aid Ltd, Pagham, UK; fig 7) . 16 

Compressors used to drive gas through the nebuliser chamber vary greatly in power and some will generate a reasonably high free air flow. However, nebuliser chambers have a resistance to flow, and attaching a nebuliser chamber to a compressor will reduce the flow considerably. Different chambers vary greatly in their resistance. To make valid comparisons between compressors, flow should be estimated with the nebuliser attached and should be measured at the outlet of the nebuliser. This is the dynamic flow and is critical in determining the droplet size and nebulisation time. dynamic flow.
group.bmj.com on October 20, 2017 -Published by http://thorax.bmj.com/ Downloaded from an aerosol indirectly. Crystals vibrate around a feeding tube, turning it into a peristaltic pump, which forces liquid through a ceramic mesh (pore size 4.6 m), creating an aerosol.
      Jet nebulisers are by far the most common type of nebuliser used worldwide. Advances in design have improved their efficiency so that the higher mass output and shorter nebulisation times seen with ultrasonic nebulisers 17 may no longer be important discriminating factors. Current ultrasonic nebulisers do not appear to nebulise drug suspensions efficiently, and until newer models are evaluated they should be avoided for this task. The evidence that they may break down complex molecules is conflicting. routine bronchodilator treatment.
17
A summary of the different types of nebulisers is given in Appendix 2 on page S42.
as if they are interchangeable. MMD is measured by some light scattering devices (see below) and only describes the aerodynamic Description of particle size output from nebulisers behaviour of particles if they are spherical and of unit density. The second and more serious Particle size in this article refers to aerodynamic particle size, meaning the size of a spherical, pitfall is the presentation of count median aerodynamic diameter (CMAD), the diameter of unit density particle that settles with the same velocity as the particle in question. A very the median number of particles in the aerosol cloud, as if it is equivalent to the MMAD (fig dense particle will have a different aerodynamic behaviour (an increased aerodynamic size) to 8). A 10 m diameter drug particle contains the same amount of drug as 1000 particles an equivalently sized but less dense particle.
Aerosols produced by medical nebulisers are of 1 m diameter. Describing the number of particles of a certain size may therefore give a heterodisperse 7 -that is, made up of particles of different sizes. Their particle size distribution very distorted view of the mass of respirable drug obtained from a nebuliser. may be described statistically (fig 8) . 21 Most therapeutic aerosols conform to an approximately log normal distribution which can be described by giving the mass median aero-    
The two most commonly used methods of dynamic diameter (MMAD) and geometric standard deviation (GSD). Perhaps a more aerosol particle size determination are laser based light scattering devices and inertial imuseful way of describing the aerosol cloud is to determine the total amount of drug contained paction devices. Unfortunately they measure different things, and each has its own drawin particles leaving the nebuliser and the amount of drug contained in particles less than backs. They are not usually interchangeable.
Ideally, comparisons of the amount of drug a certain size. Although drug contained in particles less than 5 m is described as the "res-contained in particles of various sizes from different nebulisers should use identical pirable" dose, whether all such particles are truly respirable is not certain (table 1) . measurement techniques. Laser diffraction devices, such as the MalTwo pitfalls may arise in the description of aerosol particle size (fig 8) . One is the use of vern Mastersizer (Malvern Ltd, Malvern, UK), work by passing a laser beam through the MMAD and mass median diameter (MMD) aerosol cloud. Particles diffract the light at an angle inversely related to their diameter. This diffracted light is detected by the machine 
new Malvern Mastersizer and the older Malvern 2600 particle sizers use different mathematical theories to compute particle size, and results are not necessarily interchangeable. Impaction methods of particle size determination include the glass multistage liquid impinger (MSLI), 22 the Anderson impactor, the high performance multistage liquid impinger, and the twin stage impingers described in the British Pharmacopoeia. 23 The MSLI operates by drawing the aerosol through a series Clay et al 87 Ho et al 100 Johnson et al 101 O'Doherty et al 44 Thomas et al 102 Thomas et al 17 Hardy (table 2) and particles smaller than 5 m in diameter deposit more MSLI is calibrated by passing an aerosol of known particle size through it and computing frequently in the lower airways and are appropriate for pharmaceutical aerosols. The the cut off diameters above which particles are deposited for each stage. The MSLI determines Task Group model was based on nose breathing and may underestimate the total lung deaerodynamic particle size and allows the amount of drug contained in particles below a position by ignoring mouth breathing.
The velocity of air flow decreases markedly certain aerodynamic size to be computed. The high air flow may dry out aqueous particles, in as it travels down the respiratory tract as the total cross sectional area of the airways incontrast to the high humidity of the respiratory tract, and the size of particles produced from creases. The speed of inhaled aerosol laden air and turbulent flow is greatest in the nose/ aqueous solutions may be underestimated by this method. Methodology allowing meas-mouth, pharynx, trachea and larger bronchi, and it is here that larger particles are deposited urements to be performed at high humidities may reduce this error. 24 The importance of in by impaction. Within the smaller bronchi, bronchioles, and gas exchanging tissues smaller vitro assessment of drug delivery was demonstrated by a recent study which, using a particles are removed by interception, sedimentation, and diffusion. In addition, particles suspension of an inhaled steroid, highlighted the extremely small dose produced in particles generated by nebulisers are often electrostatically charged. This charge may induce an within the respirable range, thus helping to explain the poor clinical effect of the pre-equal and opposite charge on the airway wall leading to electrostatic deposition. 28 29 This paration. 25 mechanism is most apparent for particles less than 1 m in diameter and for long thin particles such as fibres. 30 It is thought to be of less   The lung deposition characteristics and efficacy importance for the deposition of therapeutic aerosols in the lung. of an aerosol depend largely on the particle or droplet size. Generally, the smaller the particle Clark 31 has recently considered the question of whether measurements of particle diameter the greater its chance of peripheral penetration and retention. However, for very fine particles have any relevance to clinical practice by reviewing studies of radiolabelled deposition of below 0.5 m in diameter there is a chance of avoiding deposition altogether and being drug in the lung and droplet particle size measured by laser diffraction. Figure 9 plots lung exhaled. In 1966 the Task Group on Lung Dynamics, concerned mainly with the hazards aerosol deposition as a percentage of the total deposited in the patient versus the mass meof inhalation of environmental toxins, proposed a model for deposition of particles in the lung. 26 dian droplet diameter (MMD) of the nebulised aerosol cloud. A reasonable correlation was This suggested that particles of more than 10 m in diameter are most likely to deposit in found between the MMD and lung deposition.
However, the data presented only represent the the mouth and throat, for those of 5-10 m diameter a transition from mouth to airway fractionation of the aerosol cloud between the
The science of nebulised drug delivery S37 therapeutic effect. The ideal particle size to a diameter of 1 m). Generation of small particles in high concentration is difficult and delivery time is prolonged. oropharynx and the lung, and the author found insufficient data in the same papers to study the relationship between particle size and Nebuliser output penetration of aerosol into the lung periphery. In order to measure nebuliser output and to
The deposition profiles for an inhaled nebu-compare different nebulisers it is important liser cloud as predicted from the model of to use measures relevant to patients and to Rudolph et al, 32 which assumes oral breathing, standardise how those measurements are are shown in fig 10. On the assumption that made. 6 The British Standards Institute has rethe model is correct for healthy subjects, it cently published a specification for gas powered was concluded that oropharyngeal deposition nebulisers for the delivery of drugs, giving decreases with decreasing median droplet dia-definitions and a method for determining their meter, falling from 60% of the inhaled dose at output. 34 Some definitions are given in table 3. 10 m to virtually zero at 1 m. 31 Central airway Minimum standards are required of a nebuliser deposition peaks at 6-7 m and peripheral air-(see Appendix 3 on page S43), and the nebuway deposition at 2-3 m. Interestingly, the liser manufacturer must supply certain indose reaching the peripheral airways, as a frac-formation. However, the standard ignores the tion of the total inhaled, varies by less than effect of the patient's breathing pattern on the 8% over the median droplet diameter range actual dose of drug inhaled. This is essential 1-5 m. Particle deposition in the lung peri-information for the clinician who will otherwise phery is diminished in patients with broncho-have an inappropriate view of the ability of a constriction 32 33 and the optimum particle size nebuliser to deliver drug to the patient. for lung deposition in children and those with airways obstruction is less clear. In Rudolph's model the curves in fig 10 would be moved to     the left by greater impaction in the central and The mass of aerosol released has in the past upper airways of such patients. It may be better been measured simply by weighing the nebuto use finer aerosols when a high degree of liser before and after nebulisation (the graviairway obstruction is present. metric method). 3 35 This is highly inaccurate With many drugs the mass of material reach-for jet nebulisers and overestimates the drug ing the site of action is directly related to the output as weight loss due to evaporation is not taken into account (fig 11) . 36 37 The use of weight loss as a measure of aerosol output can only be used if the concentration of drug Greater (twice or more) drug delivery Effectiveness has only been shown in nebuliser to patient adults using bronchodilator solutions remaining in the nebuliser at the end of nebu-Volume fill If a nebuliser has a residual volume of 1 ml and lisation is also measured. This is then multiplied by the residual volume to give the mass of drug 2 ml of drug solution are placed into it and nebulised fully, a maximum of 50% of the drug remaining in the nebuliser which is subtracted from the mass of drug placed in the chamber will be released as aerosol (as 1 ml of the drug solution remains in the chamber). In practice at the start to give the output expressed as percentage mass emitted. 38 39 However, we have less drug will be released than this due to solvent evaporation. If 4 ml of drug solution recently shown that this method also underestimates nebuliser output by up to 100% are placed in the chamber a maximum of 75% can be released. 42 However, the larger the vol-(Barry and O'Callaghan, unpublished observations).
ume fill the longer the nebulisation time. 38 43 An alternative in vitro method of assessing nebuliser output is to collect the aerosol onto a filter or into an impactor and to assay the drug or a chemical tracer added to the nebuliser Concentration of nebuliser solution Evaporation of solvent during nebulisation solution. 40 It is important that the tracer behaves in the same way as the drug to be nebu-leads to a gradual increase in the concentration of the drug solution left behind. This leads to lised. In the laboratory the ideal method is to collect the aerosol leaving the nebuliser, assay drug wastage and explains why evaporation invalidates the gravimetric method of measthe amount of the specific drug present, and perform particle size analysis as described uring drug output. Irritation of the respiratory tract from the inhalation of highly concentrated above. The importance of taking breathing patterns into account is discussed later in the solutions may occur. section on "reality testing".
    ( 4) 7 41
Solution viscosity and surface tension Theoretically, the aerosol particle size should Driving gas flow 38 39 42 Increasing the driving gas flow through jet be proportional to the surface tension of the drug solution, but experimental work in this nebulisers will increase the drug output, reduce the particle size, 43 and decrease the nebulisation area has been conflicting. 45 46 The primary droplet size is related to surface tension and vistime. Below a certain flow drug output is negligible (fig 11) . 41 Optimum flow will depend cosity, but the baffles in jet nebulisers control the output size. Highly viscous solutions such as upon the nebuliser and drug being used, but is often 6-10 l/min. High driving gas flow rate some antibiotics 38 nebulise slowly and require powerful compressors. Warming solutions will may not be as important for nebulisers with an "open vent". When comparing different reduce viscosity and nebulisation time. McCallion et al 47 studied two ultrasonic nebulisers nebuliser/compressor combinations it is important to compare only the dynamic flow. 44 and found that the droplet size was proportional to the viscosity of the nebuliser fluid, the more viscous fluids having the lowest outputs. While there was a trend for slightly lower mass median Residual volume of drug The term residual volume is often used to infer diameter values for fluids of lower surface tension, no clear correlation was established. drug wastage 43 but residual mass of drug is the important factor and may not be directly related to the residual volume of fluid. Nebulisers which leave a low residual mass of drug are preferable. Internal baffles may be used to re-Solution temperature
The temperature of the solution may fall by 10 duce particle size, but these increase the surface area of the nebuliser and hence the residual degrees or more during jet nebulisation. 36 42 This increases the solution viscosity and revolume. Residual volume may be reduced a little by tapping the nebuliser intermittently duces the nebuliser output, 40 although the aerodynamic size of droplets produced falls with during operation.
3 Drug solutions with a lower surface tension will adhere less to the nebuliser decreasing solution temperature. 48 A jet nebuliser, Paritherm (Pari, Starnberg, Germany), surfaces, more returning to the nebuliser reservoir for re-nebulisation. Residual volume is incorporates a heating system to warm the aerosol to body temperature. effectively less and drug output is increased. 
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Environmental conditions
(increasing the amplitude of the standing waves) increases the mass output. Residual Aqueous droplets produced by jet nebulisers can lose water by evaporation. This causes an volume affects ultrasonic nebulisers in the same way as jet nebulisers, except that drug solutions increase in the concentration of the solution in the droplets and a reduction in droplet size. 49 are not concentrated as much by solvent evaporation. Solution characteristics also affect Conversely, increasing the humidity of the inhaled air may increase particle size, depending ultrasonic nebuliser output. Highly viscid solutions do not form standing waves as easily on the tonicity of the particle. 48 The relative humidity of the output of jet nebulisers is 95-and are nebulised poorly. Suspensions are also nebulised poorly, perhaps because drug part-99% so aerosol particles generated from an isotonic solution probably change very little in icles in suspension are vibrated away from the area of droplet generation. size in the respiratory tract. On the other hand, if a hypertonic solution is aerosolised the droplet size would increase in the lung while hypotonic droplets would evaporate towards Variation between types of nebuliser Different commercially available nebulisers isotonicity.
vary in the size of droplets they produce and in their nebulisation rate. One study 54 showed that the MMD of six commonly used nebuliser Static charge Particles produced by both jet and ultrasonic chambers varied from <1 m to >10 m with most in the range 4-6 m. The mass output of nebulisers may acquire an electrostatic charge. 50 51 This is an important factor in the the nebuliser chambers under the test conditions varied by a factor of four. function of spacer devices 52 but it is not known whether interaction between charged particles and the nebuliser, face mask, or mouthpiece affects drug delivery.
Variation between nebulisers of the same type and "nebuliser ageing"
There is a large variation in output between different nebulisers of the same type. 14 55-57 If Nebulisation time It is important to consider the effect of nebu-the jet is blocked with dirt or drug crystals, nebuliser output will be diminished. Repeated lisation time on patient compliance. For instance, it has been shown that 80% of the use of a singe nebuliser over time may cause a change at the critical points of droplet gennebulised dose of sodium cromoglycate from most nebulisers is delivered in the first five eration, most significantly an increase in the diameter of the air orifice. This "ageing" may minutes. 53 This sort of calculation should be made for each different drug/nebuliser com-be due to mechanical wear from the compressed air source or to excessive cleaning. bination. Increasing the length of treatment for more than 5 or 10 minutes may exasperate Increasing the diameter of the air orifice usually decreases driving pressure, reducing the air patients for little therapeutic gain.
velocity and increasing the droplet size. 55 To maintain stable generation of aerosol the driving pressure should be kept constant despite Ultrasonic nebulisers Many of the factors described above apply the resulting increase in volumetric flow. equally to ultrasonic nebulisers. Analogous to driving gas flow is the vibrational amplitude and frequency of the piezoelectric crystal. In Summary Factors affecting nebuliser output are ingeneral, higher frequencies generate smaller particles and increasing the nebuliser power extricably linked with those affecting particle size and nebulisation time. For instance, nebulisers designed to deliver small particles may have extensive internal baffles. This increases the residual volume, decreasing drug output and increasing recirculation of the nebuliser solution, thus lengthening nebulisation time.
Increasing the volume fill improves drug output but lengthens nebulisation time. Increasing driving gas flow rate may help, but for home use a higher performance compressor may be needed. Manipulation of these factors can alter drug output dramatically. In conventional jet nebulisers the aerosol is patient's inspiratory flow is greater than the appropriate control of pH, and sometimes the addition of surfactants. Additives such as citrate driving gas flow, air will be entrained, diluting the aerosol (fig 12) . The effect of this is that or phosphate buffers may also be included, or preservatives such as EDTA or benzalkonium infants and children inhale a much larger dose than adults when computed as dose per kilo-chloride. Their use and the acidity and tonicity of nebulised solutions have been linked to brongram. 58 Once children are over six months of age the dose inhaled is independent of body choconstriction in some patients. 71 72 A suspension consists of insoluble solid partsize and the per kilogram dose inhaled gradually reduces as they grow. 59 Use of an aerosol hold-icles dispersed in a liquid medium. Pharmaceutical companies usually try to formulate ing chamber may reduce the dilutional effect of air entrainment. 60 61 flocculated suspensions 73 for nebulisers because, although these sediment down rapidly, they do The breathing pattern may also affect deposition. Fast inspiration encourages inertial not form a "cake" and are easy to redisperse.
     Breathing pattern and tidal volume
Particles of drug within a suspension acquire impaction of drug in the upper airways and more central deposition. 62 Slow inspiration less-a "fluid envelope" during nebulisation. Depending on the nebuliser used and the initial ens the threshold levels of response in bronchoprovocation tests, 63 64 possibly due to in-size and shape of the drug particles they may then be too large to escape the baffle system, creased lung delivery.
resulting in very poor output, or the drug may be released in large droplets which have a high chance of upper airway deposition. In either Nose breathing The nose is an excellent filter of inhaled part-case treatment may be ineffective. 25 icles and nose breathing reduces the lung deposition of aerosols by half, 65 most of the aerosol being deposited in the anterior third of the nose. 66 67 Data are only available for adults, Importance of breathing pattern when assessing nebuliser performance: "reality however, and little is known of the particle retaining properties of the nose in childhood.
testing" of nebulisers Smaldone 74 coined the term "reality testing" of nebulisers which takes into account the breathing pattern of the patient and gives a Face mask or mouthpiece The use of a face mask with a nebuliser or more accurate reflection of the amount of drug a patient will actually receive. In a study using spacer device has been shown to be an effective method of drug delivery to children too young the gravimetric technique to determine nebuliser output 75 the Marquest Respirgard (6 ml to use a mouthpiece. 68 69 Potential problems with face masks are that some of the drug will volume fill) was reported to release 80% of the mass of the drug solution placed in it. However, land on the face, some may be inhaled through the nose, or a seal may not be achieved leading when the drug contained in an aerosol released from a nebuliser is measured on filters, much to leakage of the drug. It has been shown in vitro, using a lung model to represent the lower nebuliser efficiencies (approximately 30%) result. 76 Both of these standard methods breathing pattern of a child, that holding the face mask only 2 cm from the face may reduce fail to take the breathing pattern of the patient into account. Using a breathing simulator with drug delivery by 85%. 70 It is likely that a mouthpiece, in patients old enough to use one reliably, a tidal volume of 750 ml Smaldone 77 found that, at 20 breaths per minute and a duty time of 0.5, will increase lung deposition of drug compared with a face mask.
only 10% of the drug placed in a nebuliser would reach the patient. These results are much closer to radioisotope studies which suggest that only about 5% of drug placed within the Respirgard Drug solutions and suspensions A true molecular solution is defined as a mix-will be deposited in a patient. 74 Further refinement of in vitro techniques should result in ture of two or more components which form a homogeneous molecular dispersion in a one closer correlation with actual lung deposition measured by radioisotope deposition and pharphase system. Poor drug solubility in water may be enhanced by addition of a co-solvent, macokinetic methods.
Lung deposition measured by
be expected to increase lung bioavailability and hence overall systemic absorption. radiolabelled aerosols Measuring the lung deposition of radiolabelled
The pharmacokinetic method has been used in a comparison of two nebulisers (the Hudson aerosol takes into account the particle size distribution of the aerosol cloud and other Up-draft II and the Ventstream 1 ). Lung deposition of drug from the Ventstream should factors such as airway calibre and breathing pattern. Studies using standard two dimension theoretically be greater as it produces a larger output of respirable particles and matches the gamma scintigraphy have found the mean percentage of the dose deposited in the lung from nebuliser output to breathing pattern (see above). Measurement of plasma salbutamol a jet nebuliser to be between 2% 78 and 12%.
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Studies of a number of jet nebulisers in terms levels suggested that the Ventstream delivered approximately double the amount of drug. of bronchodilator response and intrapulmonary deposition have shown marked differences, preAn alternative method to blood sampling involves the measurement of early urinary sumably reflecting variations in nebulisation rate, output, and droplet size (table 5) . 35 80-88 excretion of salbutamol and its sulphate metabolite in order to differentiate between It may appear logical to assume that the efficacy of an aerosolised drug should be related lung and gut bioavailability. 95 to the local airway dose. In many studies, however, although regional distribution of a radiolabelled aerosol throughout the lung has been Clinical evaluation Clinical efficacy studies are ultimately the most carefully determined, it has not been related to clinical efficacy. 89 Exceptions include a study relevant measure of the effectiveness of a medication, although they may not be easy to apply by Clay et al 81 who found that nebulised bronchodilators achieve better lung deposition to an inhaled drug. For example, although bronchodilatation is characteristically rapid with smaller particles (1.8 m) than larger particles (10.3 m) and cause correspondingly after administration of a single dose of a 2 agonist, comparisons between different delivery greater bronchodilatation. Although lung deposition may be optimised by using drug part-devices may be obscured by a shallow doseresponse curve. However, incorrect conicles of 2-5 m aerodynamic diameter, it has been difficult to show that targeting specific clusions may be drawn from clinical efficiency studies unless information on the dose available airways is crucial for bronchodilator efficacy as such small doses are required for maximum for inhalation (in vitro studies) or lung dose achieved (pharmacokinetic and radioisotope bronchodilatation. Differences in the therapeutic effect of bronchodilators delivered in studies) are available. For example, in a recent paper on the emergency treatment of asthma particles of 2-5 m in diameter appear to be small. This may not be so with other drugs Campbell and colleagues 96 state that 5 mg of salbutamol given by an oxygen-driven nebuliser such as steroids and antibiotics which have a different therapeutic ratio. 89 was more effective than either 5 mg of terbutaline via a spacer or 200 g salbutamol via Although interesting information can be derived from radioisotope studies, it may be a metered dose inhaler. Review of the method provides a different interpretation. New spacers difficult to distinguish between aerosol deposition in the large airways and lung par-were used and 20 doses of terbutaline were administered by multiple actuations of the enchyma. Use of a new technique -single photon emission computed tomography (SPECT) 90 -metered dose inhaler into them, then allowing the patient to inhale (personal comprovides three dimensional images of an inhaled radio-aerosol. This may be better than planar munication). It is known that multiple actuations of metered dose inhalers into a spacer scintigraphy in showing distribution of aerosol in different parts of the lung.
substantially reduces the amount of drug available compared with repeated inhalation of a single actuation 97 and that new spacers release less drug than old ones. 98 If one can extrapolate Pharmacokinetic evaluation of lung deposition from in vitro work with other drugs it is likely that the amount of terbutaline available for There is accumulating evidence from pharmacokinetic studies to suggest that absorption inhalation from the spacers was nearer 2 mg than the 5 mg supposed. across the lung vascular bed is an important determinant of systemic bioactivity and adverse effects. 91 For example, systemic absorption of inhaled salbutamol occurs predominantly from Importance of drug targeting 99 The ability to deliver drug directly to its site of the vascular bed of the lung rather than the gut, with peak plasma concentrations being action is one of the attractions of nebuliser therapy. Apart from "in the lungs", we do not achieved within five minutes. 92 Salbutamol absorbed from the intestine undergoes extensive always know exactly where we want the drug to be deposited. Receptor sites for agonists sulphate conjugation, probably in the intestinal mucosa. Similarly, on the basis of data from occur predominantly in the small airways and for anticholinergic drugs in the larger airways. mouth rinsing and charcoal block studies 93 94 it can be inferred that the systemic bioavailability Both inhaled steroids in asthma and antibiotics in cystic fibrosis should presumably be deof inhaled corticosteroids is mainly determined by absorption across the lung vascular bed. livered to the sites of inflammation and infection, respectively, but the optimum Thus, a nebuliser delivery system which improves lung deposition would, at the same time, deposition pattern is not known. This issue needs to be considered before the best nebuliser = (8 / f 2 ) 1 / 3 for a particular treatment can be determined. where = surface tension, = density of liquid, and f = frequency of acoustic signal.
Liquid particles of radius r have a surface Conclusions area S and a volume V given by: Using the appropriate device and conditions it is possible to nebulise virtually any drug and S=4 r 2 in almost any dose. For 2 agonists, where V= 4 / 3 r 3 only a small airway dose is required to achieve maximum bronchodilatation, variation in drug If the particle is made up of a solution with mass delivery between devices may be less critical. density , the mass of the particle is given by: By contrast, the use of very expensive drugs such as rhDNase or drugs with important side M= × 4 / 3 r 3 effects such as steroids demands greater knowledge of the delivery systems used. Nebulisers vary greatly in the size of droplet Appendix 2: Types of nebuliser they produce, their nebulisation time, and drug Conventional jet nebuliser (e.g. Acorn) output. This may have a marked effect on Constant output of aerosol from the nebuliser the therapeutic response. Similarly, one cannot during both inspiration and expiration. A large assume that different drugs nebulised within amount of drug is wasted as it is produced the same nebuliser under identical conditions during expiration. will have the same output characteristics. Ideally, all nebuliser and compressor combinations and all ultrasonic nebulisers should have their output characteristics determined Conventional jet nebuliser with spacer for all drugs used. It is surprising that such basic attachment (e.g. Mizer) information is not demanded by regulatory Aerosol is continuously generated by a conauthorities when drug dose delivered may vary ventional jet nebuliser and passes into a spacer/ by 100% or more.
holding chamber. Concentrated aerosol from In order to evaluate nebuliser output a num-the spacer is inhaled during inspiration. Expired ber of factors may be measured in vitro in-air is diverted away from the chamber by a cluding the amount of drug contained in valve, allowing the chamber to fill up with particles likely to reach the airways. It is clear aerosol during this period. that this in vitro analysis must also include the effect of the patient's breathing pattern.
Laboratory evaluation will help in the choice Manual flow interrupter jet nebuliser (e.g. Pari LL) of which nebuliser to use for specific patients
The patient can exercise control over the input and drugs, and may be supplemented by measof flow of compressed air into the nebuliser ures of lung deposition by pharmacokinetic allowing nebulisation to coincide with inand/or radioisotope methods. Such an evaluspiration. ation, prior to clinical studies, may reduce the number of unnecessary trials on patients.
"Open vent" jet nebulisers (e.g. Sidestream)
Appendix 1 8 An additional vent is incorporated into the    nebuliser chamber. Negative pressure genFor a gas or liquid travelling in streamline erated by expansion of compressed air at the motion in a tube, the sum of pressure energy Venturi sucks air into the chamber via the open plus gravitational potential energy is constant. vent. This markedly increases the air flow out of the nebuliser pushing more small particles P+0.5 v 2 + gh=constant out to be inspired in a given time. Nebulisation times are shorter but the total amount received where P=pressure in the tube, =gas or liquid by the patient is similar to that for a condensity, v=gas or liquid velocity, g=grav-ventional jet nebuliser. itational acceleration, and h=height above some reference level.
"Breath assisted, open vent" jet nebulisers (e.g.     
Ventstream, Pari LC Plus)  An open vent in the nebuliser is fitted with a Mercer described the threshold of amplitude valve system which allows extra air to be pulled for the generation of capillary waves required through the nebuliser on inspiration, pulling a for aerosol generation by greater number of aerosolised particles into the inspired air stream. During exhalation the A=4v/f inspiratory valve closes, decreasing flow of air through the chamber to that from the comwhere A=threshold amplitude, v=viscosity of liquid, f=frequency of acoustic signal, and = pressor only. The result is that loss of aerosol during expiration is similar to that from a concapillary wavelength.
The mean diameter of droplets is pro-ventional jet nebuliser while that during inspiration is significantly enhanced. portional to the capillary wavelength , where
